인간성장호르몬 시장 규모, 점유율과 동향 분석 보고서 : 제품 유형별, 용도별, 투여 빈도별, 유통 채널별, 지역별, 부문 예측(2026-2040년)

Human Growth Hormone Summary

The global human growth hormone market size was estimated at USD 7.52 billion in 2025 and is projected to reach USD 28.41 billion by 2040, growing at a CAGR of 8.52% from 2026 to 2040. The main reason for the high demand of human growth hormone is adult hormone deficiency, especially Growth Hormone Deficiency (GHD). The estimated prevalence of GHD is approximately 2-3:10,000 population.

In adults, GHD may be caused by pituitary tumors, traumas to the brain, or natural aging processes, which in turn, produce a series of symptoms such as the loss of muscle mass, the distribution of fat towards the abdomen, decreased bone density, lethargy, and metabolic disturbances. The non-specific nature of these symptoms often delays diagnosis, creating a significant unmet medical need. This unmet need drives the adoption of HGH therapy, as patients seek treatment to improve quality of life, manage metabolic complications, and restore hormonal balance. Growth disorders in children, such as short stature due to GHD, remain a foundational driver of the human growth hormone market.

Technological innovations in human growth hormone delivery and formulation have significantly boosted market demand. The development of recombinant human growth hormone (rhGH) has replaced older extraction-based therapies, offering higher purity, improved safety, and consistent efficacy. These advances have expanded the therapeutic application of HGH in both pediatric growth disorders and adult hormone deficiencies, creating a larger patient base and increasing overall treatment adoption. Recent innovations such as long-acting HGH formulations and sustained-release injections have improved patient convenience by reducing the frequency of administration. The situation is improved for the patients, especially for the adults who need continuous treatment. Thus, the acceptance of HGH therapies is growing to a larger extent. Moreover, the auto-injectors and pre-filled pens have contributed to making the process of injections less painful and friendly, which in turn has positively affected the patients' acceptance and satisfaction.

The technological innovation regarding the formulation and delivery systems has been a significant growth driver in the Human Growth Hormone market. Patent activity clearly indicates a transformation towards temperature-stable formulations, sustained-release systems, and painless or non-invasive delivery methods. All these developments are intended to decrease the burden of treatment, boost patient adherence, and eliminate the daily injection-related difficulties, which in turn will lead to better clinical results and higher market acceptance.

The general trend reflected in the patents is that there is an increasing amount of R&D aimed at the transition of HGH therapy from daily injections to long-lasting, user-friendly, and technologically superior formats. The commercialization of these innovations will likely result in deeper market penetration through adherence enhancement, treatment burden reduction, and premium pricing support. The market of human growth hormones will continue to be driven by technology as the major competitive factor due to the ongoing developments in needle-free delivery, sustained-release systems, microneedle platforms, and high-stability formulations. The introduction of innovative delivery systems, such as the Easypod, an automated electronic injection device for growth hormone administration, has significantly contributed to the growth of the Human Growth Hormone market. These devices simplify the injection process, save patients' time, and reduce the risk of dosing errors, as the correct dose is programmed and verified by a healthcare professional. Such technological advancements enhance patient adherence and convenience, making HGH therapy more accessible and effective, thereby supporting market expansion.

Global Human Growth Hormone Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2040. For this study, Grand View Research has segmented the global human growth hormone market report based on product type, application, dosing frequency, distribution channel, and region:

• Product Type Outlook (Revenue, USD Million, 2021 - 2040)
• Branded Products
  • Norditropin
  • Sogroya
  • Skytrofa
  • Ngenla
  • Other
• Biosimilars
• Application Outlook (Revenue, USD Million, 2021 - 2040)
• Growth Hormone Deficiency (GHD)
  • Adult Growth Hormone Deficiency
  • Pediatric Growth Hormone Deficiency
• Turner Syndrome
• Idiopathic Short Stature
• Prader-Willi Syndrome
• Small for Gestational Age (SGA)
• Other Indications
• Dosing Frequency Outlook (Revenue, USD Million, 2021 - 2040)
• Daily hGH Injection
• Weekly hGH Injection
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2040)
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Specialty Pharmacy
• Regional Outlook (Revenue, USD Million, 2021 - 2040)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product Type
  • 1.2.2. Application
  • 1.2.3. Dosing Frequency
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Human Growth Hormone Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Human Growth Hormone Market: Product Type Business Analysis

• 4.1. Product Type Market Share, 2025 & 2040
• 4.2. Product Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product Type, 2021 to 2040 (USD Million)
• 4.4. Branded Products
  • 4.4.1. Branded Products Market, 2021 - 2040 (USD Million)
  • 4.4.2. Norditropin
    • 4.4.2.1. Norditropin Market, 2021 - 2040 (USD Million)
  • 4.4.3. Sogroya
    • 4.4.3.1. Sogroya Market, 2021 - 2040 (USD Million)
  • 4.4.4. Skytrofa
    • 4.4.4.1. Skytrofa Market, 2021 - 2040 (USD Million)
  • 4.4.5. Ngenla
    • 4.4.5.1. Ngenla Market, 2021 - 2040 (USD Million)
  • 4.4.6. Other
    • 4.4.6.1. Other Market, 2021 - 2040 (USD Million)
• 4.5. Biosimilars
  • 4.5.1. Biosimilars Market, 2021 - 2040 (USD Million)

Chapter 5. Human Growth Hormone Market: Application Business Analysis

• 5.1. Application Market Share, 2025 & 2040
• 5.2. Application Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2040 (USD Million)
• 5.4. Growth Hormone Deficiency (GHD)
  • 5.4.1. Growth Hormone Deficiency (GHD) Market, 2021 - 2040 (USD Million)
  • 5.4.2. Adult Growth Hormone Deficiency
    • 5.4.2.1. Adult Growth Hormone Deficiency, 2021 - 2040 (USD Million)
  • 5.4.3. Pediatric Growth Hormone Deficiency
    • 5.4.3.1. Pediatric Growth Hormone Deficiency, 2021 - 2040 (USD Million)
• 5.5. Turner Syndrome
  • 5.5.1. Turner Syndrome Market, 2021 - 2040 (USD Million)
• 5.6. Idiopathic Short Stature
  • 5.6.1. Idiopathic Short Stature Market, 2021 - 2040 (USD Million)
• 5.7. Prader-Willi Syndrome
  • 5.7.1. Prader-Willi Syndrome Market, 2021 - 2040 (USD Million)
• 5.8. Small for Gestational Age (SGA)
  • 5.8.1. Small for Gestational Age (SGA) Market, 2021 - 2040 (USD Million)
• 5.9. Other Indications
  • 5.9.1. Other Indications Market, 2021 - 2040 (USD Million)

Chapter 6. Human Growth Hormone Market: Dosing Frequency Business Analysis

• 6.1. Dosing Frequency Market Share, 2025 & 2040
• 6.2. Dosing Frequency Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Dosing Frequency, 2021 to 2040 (USD Million)
• 6.4. Daily hGH Injection
  • 6.4.1. Daily hGH Injection Market, 2021 - 2040 (USD Million)
• 6.5. Weekly hGH Injection
  • 6.5.1. Weekly hGH Injection Market, 2021 - 2040 (USD Million)

Chapter 7. Human Growth Hormone Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2025 & 2040
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2040 (USD Million)
• 7.4. Hospital Pharmacy
  • 7.4.1. Hospital Pharmacy Market, 2021 - 2040 (USD Million)
• 7.5. Retail Pharmacy
  • 7.5.1. Retail Pharmacy Market, 2021 - 2040 (USD Million)
• 7.6. Online Pharmacy
  • 7.6.1. Online Pharmacy Market, 2021 - 2040 (USD Million)
• 7.7. Specialty Pharmacy
  • 7.7.1. Specialty Pharmacy Market, 2021 - 2040 (USD Million)

Chapter 8. Human Growth Hormone Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2040
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2040:
• 8.4. North America
  • 8.4.1. North America Human Growth Hormone Market Estimates and Forecasts, By Country, 2021 - 2040 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Product Type Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Product Type Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. U.S. Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Product Type Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Product Type Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. Uk Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Product Type Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Product Type Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Product Type Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Product Type Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Product Type Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Product Type Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Product Type Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Product Type Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Product Type Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Product Type Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Product Type Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Product Type Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Product Type Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Product Type Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Japan Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Product Type Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. China Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Product Type Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Product Type Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Product Type Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Product Type Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait Human Growth Hormone Market Estimates and Forecasts, 2021 - 2040 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Novo Nordisk A/S
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Pfizer Inc.
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Ascendis Pharma A/S
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Sandoz International GmbH (Novartis)
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Merck KGaA / EMD Serono
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Eli Lilly and Company
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Ferring Pharmaceuticals
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. GeneScience Pharmaceuticals
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Anhui Anke Biotechnology
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. LG Chem
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives